T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment

2009 ◽  
Vol 63 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Jose Domínguez ◽  
Malú De Souza-Galvão ◽  
Juan Ruiz-Manzano ◽  
Irene Latorre ◽  
Cristina Prat ◽  
...  
2007 ◽  
Vol 45 (12) ◽  
pp. 1652-1654 ◽  
Author(s):  
D. Goletti ◽  
S. Carrara ◽  
D. Vincenti ◽  
E. Girardi

2014 ◽  
Vol 60 (3) ◽  
pp. 432-437 ◽  
Author(s):  
Virginie Rozot ◽  
Amelio Patrizia ◽  
Selena Vigano ◽  
Jesica Mazza-Stalder ◽  
Elita Idrizi ◽  
...  

2009 ◽  
Vol 58 (3) ◽  
pp. 197-204 ◽  
Author(s):  
Yoshihiro Kobashi ◽  
Keiji Mouri ◽  
Shinichi Yagi ◽  
Yasushi Obase ◽  
Naoyuki Miyashita ◽  
...  

1996 ◽  
Vol 105 (3) ◽  
pp. 416-421 ◽  
Author(s):  
S. JURCEVIC ◽  
A. HILLS ◽  
G. PASVOL ◽  
R. N. DAVIDSON ◽  
J. IVANYI ◽  
...  

Vaccine ◽  
2014 ◽  
Vol 32 (52) ◽  
pp. 7098-7107 ◽  
Author(s):  
Jaap T. van Dissel ◽  
Simone A. Joosten ◽  
Søren T. Hoff ◽  
Darius Soonawala ◽  
Corine Prins ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Cheleka A. M. Mpande ◽  
Pia Steigler ◽  
Tessa Lloyd ◽  
Virginie Rozot ◽  
Boitumelo Mosito ◽  
...  

Reversion of immune sensitization tests for Mycobacterium tuberculosis (M.tb) infection, such as interferon-gamma release assays or tuberculin skin test, has been reported in multiple studies. We hypothesized that QuantiFERON-TB Gold (QFT) reversion is associated with a decline of M.tb-specific functional T cell responses, and a distinct pattern of T cell and innate responses compared to persistent QFT+ and QFT- individuals. We compared groups of healthy adolescents (n=~30 each), defined by four, 6-monthly QFT tests: reverters (QFT+/+/-/-), non-converters (QFT-/-/-/-) and persistent positives (QFT+/+/+/+). We stimulated peripheral blood mononuclear cells with M.tb antigens (M.tb lysate; CFP-10/ESAT-6 and EspC/EspF/Rv2348 peptide pools) and measured M.tb-specific adaptive T cell memory, activation, and functional profiles; as well as functional innate (monocytes, natural killer cells), donor-unrestricted T cells (DURT: γδ T cells, mucosal-associated invariant T and natural killer T-like cells) and B cells by flow cytometry. Projection to latent space discriminant analysis was applied to determine features that best distinguished between QFT reverters, non-converters and persistent positives. No longitudinal changes in immune responses to M.tb were observed upon QFT reversion. M.tb-specific Th1 responses detected in reverters were of intermediate magnitude, higher than responses in QFT non-converters and lower than responses in persistent positives. About one third of reverters had a robust response to CFP-10/ESAT-6. Among those with measurable responses, lower proportions of TSCM (CD45RA+CCR7+CD27+) and early differentiated (CD45RA-) IFN-γ-TNF+IL-2- M.tb lysate-specific CD4+ cells were observed in reverters compared with non-converters. Conversely, higher proportions of early differentiated and lower proportions of effector (CD45RA-CCR7-) CFP10/ESAT6-specific Th1 cells were observed in reverters compared to persistent-positives. No differences in M.tb-specific innate, DURT or B cell functional responses were observed between the groups. Statistical modelling misclassified the majority of reverters as non-converters more frequently than they were correctly classified as reverters or misclassified as persistent positives. These findings suggest that QFT reversion occurs in a heterogeneous group of individuals with low M.tb-specific T cell responses. In some individuals QFT reversion may result from assay variability, while in others the magnitude and differentiation status of M.tb-specific Th1 cells are consistent with well-controlled M.tb infection.


1995 ◽  
Vol 63 (4) ◽  
pp. 1491-1497 ◽  
Author(s):  
H Boesen ◽  
B N Jensen ◽  
T Wilcke ◽  
P Andersen

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 670 ◽  
Author(s):  
Aleksandar Murgaski ◽  
Pauline M. R. Bardet ◽  
Sana M. Arnouk ◽  
Emile J. Clappaert ◽  
Damya Laoui

Recent advances in cancer immunotherapy have mainly focused on re-activating T-cell responses against cancer cells. However, both priming and activation of effector T-cell responses against cancer-specific antigens require cross-talk with dendritic cells (DCs), which are responsible for the capturing, processing and presentation of tumour-(neo)antigens to T cells. DCs consequently constitute an essential target in efforts to generate therapeutic immunity against cancer. This review will discuss recent research that is unlocking the cancer-fighting potential of tumour-infiltrating DCs. First, the complexity of DCs in the tumour microenvironment regarding the different subsets and the difficulty of translating mouse data into equivalent human data will be briefly touched upon. Mainly, possible solutions to problems currently faced in DC-based cancer treatments will be discussed, including their infiltration into tumours, activation strategies, and antigen delivery methods. In this way, we hope to put together a broad picture of potential synergistic therapies that could be implemented to harness the full capacity of tumour-infiltrating DCs to stimulate anti-tumour immune responses in patients.


2000 ◽  
Vol 181 (5) ◽  
pp. 1850-1854 ◽  
Author(s):  
Sandra M. Arend ◽  
Peter Andersen ◽  
Krista E. van Meijgaarden ◽  
Rikke L. V. Skjøt ◽  
Yanri W. Subronto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document